XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Cell-Based Immunotherapy vs. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

JANUARY 28, 2022

Kimmtrak is part of a novel class of bispecific T cell immunotherapies being developed by Immunocore. Kimmtrak has also become the first bispecific T cell engager to be FDA-approved for the treatment of a solid tumor. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Development 52

Development Drugs Clinical Development Antibody 52

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. The post Immunocore gets EU nod for TCR cancer therapy Kimmtrak appeared first on. ” Image by Pexels from Pixabay .

Protein 52

Protein Sales Drugs Trials 52

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. .

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Delveinsight

FEBRUARY 25, 2021

Beam employs three approaches to deliver its genetic medicines to cells. Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The company’s in vivo therapies reach the eye and central nervous system via adeno-associated viruses, while its liver therapies employ lipid nanoparticles (LNPs).

DNA 52

DNA In-Vivo Genetics Medicine 52

The Pharma Data

MARCH 23, 2022

Their investigation reveals that an experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells. who co-led the Cell Reports study with Scripps Research Professor Juan Carlos De La Torre, Ph.D., who co-led the Cell Reports study with Scripps Research Professor Juan Carlos De La Torre, Ph.D.,

Protein 52

Protein Genome Genomics Research 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Hoffmann-La Roche is the leading patent filer in the peptide nano-particle conjugates space.

Antibody 130

Antibody DNA Development Vaccination 130

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. About Trimer-Tag© Technology. S-Trimer is intended to be adjuvanted. About CpG 1018.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

OCTOBER 21, 2020

21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. The disease is a subtype of ALL in which the cancer cells have a genetic abnormality called the Philadelphia chromosome (Ph). WEDNESDAY, Oct.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

OCTOBER 21, 2020

21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. The disease is a subtype of ALL in which the cancer cells have a genetic abnormality called the Philadelphia chromosome (Ph). WEDNESDAY, Oct.

Drugs 52

Drugs Genetics Trials Research 52

XTalks

JANUARY 19, 2024

Therapeutic radiopharmaceuticals deliver beta or alpha radiation, which destroys diseased cells, such as cancer cells. The aim of these compounds is to deliver radiation directly to the tumor cells, minimizing damage to surrounding healthy tissues. There have been more than $1.7

DNA 66

DNA Radiology FDA Approval Development 66

pharmaphorum

MARCH 27, 2022

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. In the US, Abecma has a list price of around $420,00, while J&J has set its therapy a little higher at $465,000.

Antibody 98

Antibody Clinical Trials Clinical Trials Sales 98

Delveinsight

DECEMBER 3, 2020

Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Janssen buys a gene therapy asset. Janssen buys a new gene therapy aimed at reversing a severe disease, from Hemera Biosciences.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Damian Trojanowski, Dr, R&D Specialist, Antibody Discovery Group, Pure Biologics, on: ‘Anti-GARP/TGFb1 antibodies in new twist – multifunctional shapers of anti-tumour immunity’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

OCTOBER 21, 2022

Take, for example, its use for CD4 T cell counting to facilitate HIV monitoring. Flow cytometry is a technique used to rapidly analyse single cells in order to characterise their physical, chemical and biological properties. . Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

The Pharma Data

MAY 4, 2021

and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced renal cell carcinoma; as well as. Inlyta globally, up 34% operationally, primarily reflecting increased demand in the U.S.

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

MAY 5, 2021

Affinia Therapeutics raises $110 million for gene therapy treatments ( STAT ). Athenex shares soar with buyout of natural killer T cell player ( Endpoints ). Startup sets out to tackle the gene therapy manufacturing crisis ( Endpoints ). Medtech. Medtech.

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52